Novartis AG (SWX:NOVN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 185.74B |
| Revenue (ttm) | 46.87B |
| Net Income (ttm) | 10.82B |
| Shares Out | 1.90B |
| EPS (ttm) | 5.32 |
| PE Ratio | 18.40 |
| Forward PE | 13.20 |
| Dividend | 3.50 (3.57%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 4,254,228 |
| Average Volume | 4,667,259 |
| Open | 98.40 |
| Previous Close | 98.12 |
| Day's Range | 97.88 - 99.30 |
| 52-Week Range | 83.63 - 102.72 |
| Beta | 0.49 |
| RSI | 50.47 |
| Earnings Date | Apr 29, 2025 |
About Novartis AG
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial numbers in USD Financial StatementsNews
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
On Thursday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE: NVS) oral Fabhalta (iptacopan) for adults with C3 glomerulopathy (C3G) to reduce proteinuria (protein in the uri...
Novartis receives third FDA approval for oral Fabhalta treatment for kidney disease C3G
Novartis receives third FDA approval for oral Fabhalta treatment for kidney disease C3G
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Phase III study showed sustained proteinuria reduction at one year with favorable safety1 Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause of C...
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta ® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders
Monte Rosa's MRT-6160 shows promising Phase 1 ... Full story available on Benzinga.com
PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July
On Thursday, PTC Therapeutics, Inc. (NASDAQ: PTCT) shared new data from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics and Genom...
Novartis succeeds in trials for spinal muscular atrophy treatment in 2 to 18-year-olds
Novartis' OAV101 IT gene therapy shows promising results for spinal muscular atrophy patients aged 2-18, improving motor function in late-stage trials. Read more here.
Novartis scraps use of diverse panels for hires in US
Swiss drugmaker Novartis is ending its use of diverse panels for all of its hiring in the United States, the company told Reuters on Wednesday, citing the changing legal and policy landscape surroundi...
Novartis CEO says it is watching US reciprocal tariff policy 'very carefully'
Swiss pharmaceutical giant Novartis says it is watching "very carefully" how the reciprocal tariff policy proposed by the United States would unfold in early April, Chief Executive Vas Narasimhan said...
Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032: Nantomics, Genentech, and Novartis are Pivotal in the Development of the $16.4 Billion Market
Dublin, March 14, 2025 (GLOBE NEWSWIRE) -- The "Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. A newly revealed compreh...
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
H.C. Wainwright & Co. initiated coverage on Thursday for Perspective Therapeutics, Inc. (NASDAQ: CATX), a clinical-stage biotechnology company advancing “targeted radiotherapy agents” for cancer trea...
Novartis becomes first pharma partner of the NFL
NFL signs Novartis as first pharmaceutical partner-source
The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based firm Novartis , a league source told Reuters on Thursday.
Novartis Pharmaceuticals and Folia Health Partner on Innovative App-Based Study to Assess Real-World Experience of IgA Nephropathy
BOSTON, March 13, 2025 (GLOBE NEWSWIRE) -- Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initi...
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
Basel, March 7, 2025 – Novartis shareholders today agreed to the Board of Directors' recommendations for all proposed resolutions at the company's Annual General Meeting (AGM). A total of 1,693 shareh...
10 Dividend Aristocrat Bargains To Help You SWAN During This Trade War Turmoil
The trade war is causing market volatility, with stocks falling and bonds performing well as investors seek hedges against economic slowdown fears. Dividend aristocrats, particularly low-volatility, d...
Novartis not panicking over potential US pharmaceutical tariffs, chairman says
Novartis is not panicking about higher tariffs on pharmaceutical imports that U.S. President Donald Trump could impose, the drug maker's Chairman Joerg Reinhardt said in an interview published on Thur...
Final Trade: NVS, XLU, GM
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Final Trade: NVS, XLU, GM
The final trades of the day with CNBCs Melissa Lee and the Fast Money traders.
Novartis AG (NVS) Showcases Promising Data at AAAAI and AAD Meetings
Novartis AG (NVS) Showcases Promising Data at AAAAI and AAD Meetings
Novartis gets EU positive recommendation for its kidney disease treatment
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS to be presented New analyses of 52-week data from Phase III ...
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
Basel, February 28, 2025 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended...
Why Novartis Remains A 'Buy' After Beating Expectations Again
Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read why I maintain my Buy rating on NVS.